Y1.7LI tumor bearing mice were treated with (1) control mAb, (2) anti-CTLA-4, (3) anti-PD-1, (4) anti-CTLA-4 + anti-PD-1, (5) control VAX (irrelevant SLP + pI:C), or (6) neo VAX (mLama4 SLP + pI:C) beginning on day 7 (Figure 2A). Here, PDCD1 is linked to neoplasm.